fbpx Skip to main content

FRIDAY, Oct. 23, 2020 (HealthDay News) — For patients with psoriasis, survival from COVID-19 is high, with increased hospitalization risk in association with nonbiologic systemic therapy versus biologic use, according to a study published online Oct. 16 in the Journal of Allergy and Clinical Immunology.

Satveer K. Mahil, M.D., Ph.D., from Guy’s and St. Thomas’ NHS Foundation Trust in London, and colleagues characterized the course of COVID-19 in psoriasis and identified factors associated with hospitalization using data from an international registry.

The researchers found that 71, 18, and 10 percent of the 374 clinician-reported patients from 25 countries were receiving a biologic, a nonbiologic, and no systemic treatment for psoriasis, respectively. Overall, 93 percent of the patients fully recovered from COVID-19; 22 and 2 percent were hospitalized and died, respectively. The risk for hospitalization was increased in association with older age (multivariable-adjusted odds ratio [OR], 1.59 per 10 years), male sex (OR, 2.51), non-White ethnicity (OR, 3.15), and comorbid chronic lung disease (OR, 3.87). Patients using nonbiologic systemic therapy were hospitalized more frequently than those on biologics (odds ratio, 2.84). There were no significant differences noted between biologic classes. Lower levels of social isolation were suggested in individuals receiving nonbiologic systemic therapy compared with biologics (OR, 0.68) using independent patient-reported data (1,626 patients across 48 countries).

“We can reassure our patients that the survival for people with psoriasis is high, and the risk factors for psoriasis patients are similar to those of the general population,” Mahil said in a statement.

Several authors disclosed financial ties to the pharmaceutical industry.

You May Also Like::  Decrease Seen in Non-COVID-19-Related Hospitalizations at Peak

Abstract/Full Text (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More